Transferase Other Than Ribonuclease (2.) Patents (Class 435/193)
  • Patent number: 11119095
    Abstract: Provided is a method for measuring tyrosine phosphatase and tyrosine kinase activity, as a high-sensitivity measuring method, which is suitable for high throughput and which uses a compound represented by general formula (I) (in the formula, A represents a conjugated ring; L represents a linker or the like having a labeling substance at an end; R1 represents a hydrogen atom or the like; and R2 and R3 each represent a hydrogen atom, an alkyl group or the like).
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: September 14, 2021
    Assignee: TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Shinichi Sato, Hiroyuki Nakamura, Hirofumi Nakano
  • Patent number: 11116817
    Abstract: The present invention is directed to antimicrobial agents and compositions including the same. The antimicrobial agent can include a polypeptide or a peptidomimetic of the polypeptide. The polypeptide can have a net positive charge of at least about 3 at a pH of 7.0, and a hydrophobicity of greater than 25%.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: September 14, 2021
    Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURI
    Inventors: Shuping Zhang, Ming Yang
  • Patent number: 11098292
    Abstract: The present disclosure provides engineered transaminase polypeptides useful for the synthesis of chiral amine compounds under industrially relevant conditions. The disclosure also provides polynucleotides encoding the engineered transaminase polypeptides, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases for the production of chiral amine compounds.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: August 24, 2021
    Assignee: Codexis, Inc.
    Inventors: Martina Quintanar-Audelo, Ellen Eberhard, Jovana Nazor, Derek Smith, Cuixia Wang
  • Patent number: 10981980
    Abstract: Provided herein are new compositions and methods to target and deliver agents to pathological areas by utilizing multifunctional compounds. These compounds include three or more domains: (i) a vimentin-binding peptide, (ii) a linker, and (iii) a drug binding, a capturing reagent, or a detectable moiety. These compounds can be used to detect, isolate, and/or treat cancerous cells such as circulating tumor cells.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: April 20, 2021
    Assignee: Counterpoint Biomedica LLC
    Inventors: Frederick L. Hall, Erlinda M. Gordon
  • Patent number: 10941215
    Abstract: The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: March 9, 2021
    Assignee: Genentech, Inc.
    Inventors: Mark Dennis, Ryan Jefferson Watts, Yunhua Yu Zuchero, Yin Zhang
  • Patent number: 10927393
    Abstract: A method includes combining a polynucleotide and an amplification reagent mixture to form a reaction mixture, wherein the reaction mixture comprises reversibly bound divalent ions in solution, and adjusting the pH of the reaction mixture to release the reversibly bound divalent ions, thereby initiating amplification of the polynucleotide.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: February 23, 2021
    Assignee: Ionian Technologies, LLC
    Inventors: Honghua Zhang, Jarrod Provins, Richard Roth
  • Patent number: 10913971
    Abstract: Provided is GDH with increased applicability to glucose sensors. A composition contains FADGDH, wherein when 0.1 mL of the composition is added to 2.9 mL of a solution containing 10 mM of trehalose and 1 mmol/L of potassium ferricyanide to give a glucose dehydrogenase activity of 500 U/mL and incubated at 37° C., the decrease in absorbance at 405 nm resulting from reduction of the potassium ferricyanide is less than 20 mAbs per minute.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: February 9, 2021
    Assignee: TOYOBO CO., LTD.
    Inventors: Yuu Utashima, Takahide Kishimoto
  • Patent number: 10876102
    Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: December 29, 2020
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Kyle Seamon, Andrew Garst
  • Patent number: 10876099
    Abstract: The present invention relates to preparation and application of a cyclodextrin glucosyltransferase mutant, belonging to the fields of gene engineering and enzyme engineering. By mutating amino acids of cyclodextrin glucosyltransferase, the enzyme activity of the obtained mutant can reach 2.5 times that of wild enzyme. In addition, the cyclodextrin glucosyltransferase mutant obtained in the present invention is simple in purification and suitable for industrial production.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: December 29, 2020
    Assignee: Jiangnan University
    Inventors: Jing Wu, Lingqia Su, Xiumei Tao, Yusheng Wang, Junchen Dong
  • Patent number: 10844091
    Abstract: The invention includes a tetrapeptide to be used in the treatment of Alzheimer's disease and depression. The tetrapeptide comprises the general formula, acetyl-X-ARG-ARG-amide, where X=-(D-ARG)-ARG-; -(D-LYS)-LYS-; or -(D-MET)-MET-. On the basis of the combination of pharmacological properties identified, a preparation including the tetrapeptide has potential for clinical use as a nootropic, neuroprotective, and antidepressant agent.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 24, 2020
    Assignee: “VERTA RESEARCH-PRODUCTION COMPANY”LTD
    Inventors: Roman Danilovich Dejko, Alexandr Alexandrovich Kolobov, Elena Arturovna Kampe-Nemm, Vladimir Michajlovich Shpen
  • Patent number: 10829519
    Abstract: Angiotensin (1-7) analogs are provided. Also provided are methods of making such analogs methods for using analogs as therapeutic compositions such as, for example, treatment cancer.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: November 10, 2020
    Assignees: WAKE FOREST UNIVERSITY HEALTH SCIENCES, TENSIVE CONTROLS, INC.
    Inventors: Patricia Gallagher, Ann Tallant, Daniel Yohannes, Kenneth A. Gruber
  • Patent number: 10801044
    Abstract: A method of producing a long-chain fatty alcohol, containing culturing a microorganism wherein expression of a gene encoding a 3-ketoacyl-ACP synthase and expression of a gene encoding a fatty acyl-CoA reductase are enhanced; a method of providing ability to produce a long-chain fatty alcohol for a microorganism wherein expression of a gene encoding a 3-ketoacyl-ACP synthase and expression of a gene encoding a fatty acyl-CoA reductase are enhanced in a microorganism cell; and a transformant of a microorganism in which expression of a gene encoding a ?-ketoacyl-ACP synthase and expression of a gene encoding a fatty acyl-CoA reductase are enhanced.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: October 13, 2020
    Assignee: Kao Corporation
    Inventors: Mika Terai, Akihito Kawahara, Tatsuro Ozaki
  • Patent number: 10760117
    Abstract: Disclosed are methods for polynucleotide sequencing that detect the location of selected nucleobases with greater precision. The methods can be used to determine the location and nature of modified bases in a polynucleotide, that is, non-canonical bases, or to improve accuracy of sequencing of “problem” regions of DNA sequencing such as homopolymers, GC rich areas, etc. The sequencing method exemplified is nanopore sequencing. Nanopore sequencing is used to generate a unique signal at a point in a polynucleotide sequence where an abasic site (AP site, or apurinic or apyrimidinic site) exists. As part of the method, an abasic site is specifically created enzymatically using a DNA glycosylase that recognizes a pre-determined nucleobase species and cleaves the N-glycosidic bond to release only that base, leaving an AP site in its place.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: September 1, 2020
    Assignee: The Regents of the University of California
    Inventors: Miten Jain, Hugh Edward Olsen, Mark A. Akeson
  • Patent number: 10752901
    Abstract: Methods for treating angiogenesis-mediated diseases are disclosed. More particularly, the present disclosure relates to methods of inhibiting ferrochelatase as an antiangiogenic therapy.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: August 25, 2020
    Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Timothy Corson, Halesha Basavarajappa
  • Patent number: 10717982
    Abstract: The present invention relates to nucleic acid molecules containing poly (dA:dT) regions which are stabilized in E. coli, methods of propagating such nucleic acid molecules in E. coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly (dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: July 21, 2020
    Assignees: BioNTech RNA Pharmaceuticals GmbH, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
    Inventors: Florian Eberle, Ugur Sahin, Andreas Kuhn, Britta Vallazza, Mustafa Diken
  • Patent number: 10597665
    Abstract: A method is provided for modifying yeast to express mutant avian farnesyl disphospate synthase and the resulting modified yeast. The yeast advantageously includes additional mutants including but not limited to having ergosterol dependent growth and being erg-. The modified yeast are beneficial for the production of various terpenes including diterpenes.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: March 24, 2020
    Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Joe Chappell, Xun Zhuang, Shuiqin Wu
  • Patent number: 10570177
    Abstract: Herein provided are peptide inhibitors and methods for treating polyglutamine (polyQ) diseases. Also disclosed are related compositions and kits for therapeutic use in the treatment of polyQ diseases.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: February 25, 2020
    Assignees: The Chinese University of Hong Kong, University of Copenhagen
    Inventors: Ho Yin Edwin Chan, Knud J. Jensen, Jacky Chi Ki Ngo, Kasper K Sorensen, Qian Zhang, Zhong Zuo
  • Patent number: 10562932
    Abstract: Disclosed herein are synthetic peptides and compositions comprising the same for the treatment and/or prophylaxis of a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma. Also disclosed herein are methods of treating and/or preventing a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: February 18, 2020
    Assignee: MACKAY MEMORIAL HOSPITAL
    Inventors: Yeou-Ping Tsao, Tsung-Chuan Ho
  • Patent number: 10538747
    Abstract: Provided are a novel separated polypeptide having transaminase activity, a polynucleotide encoding the polypeptide, a microorganism including the polynucleotide, and a method of deaminating an amino compound by using the polypeptide or the microorganism.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: January 21, 2020
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Jae Hun Lee, Young Lyeol Yang, In Seok Oh
  • Patent number: 10463594
    Abstract: A method for perming or coloring hair, in which hair is treated with a cosmetic composition including a protein-glutaminase and not including an alkaline substance. A method of enhancing hair-permeation of an active ingredient included in a cosmetic composition, in which a protein glutaminase is included in the cosmetic composition. The cosmetic composition does not include an alkaline substance, and the active ingredient is at least one of a hair perm agent and a hair coloring agent.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: November 5, 2019
    Assignee: AJINOMOTO CO., INC.
    Inventors: Keiichi Yokoyama, Eiko Oshimura, Masayo Date, Yukiko Umezawa
  • Patent number: 10421985
    Abstract: The present invention relates to a transformed mammalian cell including a heterologous nucleic acid sequence (i) encoding a polypeptide including the catalytic domain of ST6Gal1 or of ST6Gal2 and, optionally, at least one nucleic acid sequence (ii) encoding a therapeutic protein including at least one glycosylation site, the transformed mammalian cell expressing the therapeutic protein with a sialylation on the at least one glycosylation site.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: September 24, 2019
    Assignee: GLYCOTREK
    Inventor: Catherine Ronin
  • Patent number: 10415069
    Abstract: The invention provides compositions and methods for engineering bacteria to produce sialylated and N-acetylglucosamine-containing oligosaccharides, and the use thereof in the prevention or treatment of infection.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: September 17, 2019
    Assignee: Glycosyn LLC
    Inventors: Massimo Merighi, Matthew Ian Heidtman, John M. McCoy
  • Patent number: 10415023
    Abstract: The present invention addresses a problem of providing a lipase derived from a microorganism that is specific for short-chain to medium-chain fatty acids. A modified lipase is obtained by making a substitution in the amino acid sequence of a Candida cylindracea derived lipase, wherein the substitution is (1) a substitution of asparagine for an amino acid corresponding to the amino acid at position 428 in the amino acid sequence set forth in SEQ ID NO: 1; or (2) a substitution of phenylalanine, methionine, or isoleucine for an amino acid corresponding to the amino acid at position 429 in the amino acid sequence set forth in SEQ ID NO: 1.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: September 17, 2019
    Assignee: AMANO ENZYME INC.
    Inventors: Yuki Ishigaki, Satoru Ishihara, Shun-ichi Tanaka
  • Patent number: 10392642
    Abstract: High molecular weight heparosan polymers are described, as are methods of producing and using the high molecular weight heparosan polymers.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: August 27, 2019
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Paul L. DeAngelis, Phillip E. Pummill, Regina C. Visser
  • Patent number: 10329578
    Abstract: Compositions and methods comprising polynucleotides and polypeptides having glyphosate-N-acetyltransferase (GLYAT) activity are provided. In specific embodiments, the sequence has an improved property, such as, but not limited to, an improved specificity for glyphosate when compared to an appropriate control resulting in decreased off target acetylation of, e.g. an amino acid such as aspartate. Further provided are nucleic acid constructs, plants, plant cells, explants, seeds and grain having the GLYAT sequences. Various methods of employing the GLYAT sequences are provided. Such methods include methods for producing a glyphosate tolerant plant, plant cell, explant or seed and methods of controlling weeds in a field containing a crop employing the plants and/or seeds disclosed herein.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: June 25, 2019
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Ericka Bermudez, Linda A. Castle, Kevin E. McBride, Daniel Siehl
  • Patent number: 10307458
    Abstract: As described herein, an peptide of SEQ ID NO: 1 is modified at the terminal end. Specifically, the carboxyl-group of the leucine at the terminal end of the amino acid sequence FCIGRL (SEQ ID NO: 1) is modified with a —CONH2. This modified peptide is used as a permeation enhancer to boost the mucous membrane permeation, thereby noticeably increasing the bioavailability of a drug that is administered together with the modified peptide. The drug to be administered with the modified peptide can be cyclosporine A.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: June 4, 2019
    Assignee: Soonchunhyang University Industry Academy Cooperation Foundation
    Inventor: Keon-Hyoung Song
  • Patent number: 10286038
    Abstract: A group of LIMP-2 peptides, LIMP-2 polypeptides, variants thereof, and pharmaceutical compositions comprising the LIMP-2 peptides, LIMP-2 polypeptides, or variants thereof are described. The disclosed peptides and polypeptides preferably comprise an amino acid sequence that is sufficient for providing a biological activity associated with LIMP-2, which may include binding and/or activating biological molecules such as ?-glucocerebrosidase and binding viral protein 1 (VP1) of enterovirus 71 (E71) or coxsackievirus A16 (CA16). Also disclosed are methods of using the LIMP-2 peptides, LIMP-2 polypeptides, and variants thereof as therapeutics for treating diseases and disorders associated with ?-glucocerebrosidase activity in subjects in need thereof.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: May 14, 2019
    Assignee: Northwestern University
    Inventors: Michael Schwake, Dimitri Krainc
  • Patent number: 10287612
    Abstract: Provided is a cyanobacterium improved in fatty acid productivity. A method for producing a modified cyanobacterium, comprising causing loss of function of a LexA transcriptional regulator and acyl-ACP synthetase in a cyanobacterium.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: May 14, 2019
    Assignees: Kao Corporation, Saitama University
    Inventors: Akihito Kawahara, Yukako Sonoike, Ayumi Kizawa
  • Patent number: 10233247
    Abstract: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: March 19, 2019
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Nobuo Hanai, Kazuyasu Nakamura, Emi Hosaka, Motoo Yamasaki, Kazuhisa Uchida, Toyohide Shinkawa, Susumu Imabeppu, Yutaka Kanda, Naoko Yamane, Hideharu Anazawa
  • Patent number: 10119127
    Abstract: Glutamine phenylpyruvate transaminase (GPT) proteins, nucleic acid molecules encoding GPT proteins, and uses thereof are disclosed. Provided herein are various GPT proteins and GPT gene coding sequences isolated from a number of plant species. As disclosed herein, GPT proteins share remarkable structural similarity within plant species, and are active in catalyzing the synthesis of 2-hydroxy-5-oxoproline (2-oxoglutaramate), a powerful signal metabolite which regulates the function of a large number of genes involved in the photosynthesis apparatus, carbon fixation and nitrogen metabolism.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: November 6, 2018
    Assignees: Los Alamos National Security, LLC, University of Maine System Board of Trustees
    Inventors: Pat J Unkefer, Penelope S Anderson, Thomas J Knight
  • Patent number: 10104883
    Abstract: The present invention generally relates to non-aqueous solutions of plant growth regulator(s) and polar and/or semi-polar organic solvent(s), methods for making said non-aqueous solution, and methods for improving the growth and crop productivity of plants using said non-aqueous solution.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: October 23, 2018
    Assignee: Stoller Enterprises, Inc.
    Inventors: Jerry Stoller, Ritesh Sheth
  • Patent number: 10046009
    Abstract: The invention relates to a pharmaceutical composition containing a PLP-dependent enzyme and optionally its cofactor, pyridoxal phosphate (PLP), and/or a phosphate or non-phosphate precursor of PLP, its use as a drug, its production method and a therapeutic treatment method related to it. The pharmaceutical composition comprises erythrocytes and a pharmaceutically acceptable vehicle, the erythrocytes encapsulating the PLP-dependent enzyme. The PLP-dependent enzyme may be methioninase, tyrosine phenol-lyase, tyrosine aminotransferase or cystathionine beta-synthase.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: August 14, 2018
    Assignee: ERYTECH PHARMA
    Inventors: Yann Godfrin, Vanessa Bourgeaux, Fabien Gay, Thomas Cortese
  • Patent number: 10017769
    Abstract: The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: July 10, 2018
    Assignee: INSTITUT PASTEUR
    Inventors: Philippe Despres, Sylvie Paulous, Elodie Crublet
  • Patent number: 10011839
    Abstract: The disclosure relates to a metabolic transistor in microbes such as bacteria and yeast where a competitive pathway is introduced to compete with a product pathway for available carbon so as to control the carbon flux in the microbe.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: July 3, 2018
    Assignee: William Marsh Rice University
    Inventors: Ka-Yiu San, George N. Bennett, Hui Wu
  • Patent number: 9951356
    Abstract: Modification of metabolic pathways includes genetically engineering at least one enzyme involved in elongating 2-ketoacids during leucine biosynthesis, and preferably at least isopropylmalate dehydrogenase or synthase (LeuB or LeuA in E. coli), to include at least such non-native enzyme, enzyme complex, or combination thereof to convert 2-ketobutyrate or 2-ketoisovalerate to a C7-C11 2-ketoacid, wherein the production of such is at a higher efficiency than if a purely native pathway is followed. The C7-C11 2-ketoacid may then be converted, via a native or genetically engineered thiamin dependent decarboxylase, to form a C6-C10 aldehyde having one less carbon than the C7-C11 2-ketoacid being converted. In some embodiments the C6-C10 aldehyde may then be converted via additional native or genetically engineered enzymes to form other C6-C10 products, including alcohols, carboxylic acids, and alkanes.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: April 24, 2018
    Assignee: Dow Global Technologies LLC
    Inventors: Paresh C. Sanghani, Brandon A. Rodriguez, Christopher C. Stowers, Amudhan Venkateswaran
  • Patent number: 9944965
    Abstract: The present invention relates to methods for production of 2?Fucosyllactose by a microbial system comprising a ?-1,2 fucosyltransferase (FucT2) polynucleotide and a Guanosine 5?-diphospho-?-L-fucose (GDP-L-fucose) synthesis pathway using lactose as a substrate. Furthermore, the present invention relates to compositions comprising the microbial system.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: April 17, 2018
    Assignees: The Board of Trustees of the University of Illinois, Seoul National University R&DB Foundation
    Inventors: Won-Heong Lee, Panchalee Pathanibul, Josh Quarterman, Michael J. Miller, Yong-Su Jin, Jin-Ho Seo
  • Patent number: 9944963
    Abstract: The present disclosure relates to polypeptides having transaminase activity, polynucleotides encoding the polypeptides, and methods of using the polypeptides.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: April 17, 2018
    Assignee: Codexis, Inc.
    Inventors: Christopher K. Savile, Emily Mundorff, Jeffrey C. Moore, Paul N. Devine, Jacob M. Janey
  • Patent number: 9896696
    Abstract: Compositions and methods for modifying genomic DNA sequences are provided. The methods produce double-stranded breaks (DSBs) at pre-determined target sites in a genomic DNA sequence, resulting in mutation, insertion, and/or deletion of DNA sequences at the target site(s) in a genome. Compositions comprise DNA constructs comprising nucleotide sequences that encode a Cpf1 or Csm1 protein operably linked to a promoter that is operable in the cells of interest. The DNA constructs can be used to direct the modification of genomic DNA at pre-determined genomic loci. Methods to use these DNA constructs to modify genomic DNA sequences are described herein. Additionally, compositions and methods for modulating the expression of genes are provided.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: February 20, 2018
    Assignee: Benson Hill Biosystems, Inc.
    Inventors: Matthew Begemann, Benjamin Neil Gray
  • Patent number: 9868971
    Abstract: Disclosed are methods and kits for controlling the length of overhangs at the ends of double stranded DNA based on a competitive inhibition. Further provided are ligase-independent methods for joining the two ends of DNA strands using the same. The present methods efficiently control the overhangs of ds DNA. This user-controlled overhangs supply a tool for efficient ligation in a ligase independent way and can be advantageously used in DNA recombinant technology such as cloning gene or DNA fragments of interest or PCR products.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: January 16, 2018
    Assignee: ENZYNOMICS CO. LTD.
    Inventors: Yong Keol Shin, Yunil Suh, Min Young Lee, Ah Rong Jeong
  • Patent number: 9856302
    Abstract: An antimicrobial peptide which is a derivative of the peptide P-113. The amino acid sequence of the antimicrobial peptide is SEQ ID NO: 4 or SEQ ID NO: 5, in which the C-terminus is or is not modified with a NH2.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: January 2, 2018
    Assignee: GENERAL BIOLOGICALS CORPORATION
    Inventors: Wen-Chi Cheng, Ming-Sun Liu, Frank Lin, Chung-Yu Lan, Guan-Yu Lin, Hsueh-Fen Chen
  • Patent number: 9856291
    Abstract: A synthetic peptide that targets cancer stem cells is provided. The peptide consists of the amino acid sequence of anyone of SEQ ID NO: 1 to SEQ ID NO: 15. Also provided is a composition comprising said synthetic peptide with a therapeutic agent fused thereto, and a pharmaceutically acceptable carrier or diluent. Further provided is a method of screening a peptide specifically targeting to a cancer stem cell. The method comprises the steps of establishing an oligopeptide library by using a phage expression system, contacting the library with a culture of bulk tumor cells of a cancer cell line, contacting the phages which do not bind to the bulk tumor cells with a culture of cancer stem cells of said cancer cell line, and screening a peptide specifically targeting to a cancer stem cell from the phages which bind to the cancer stem cells.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: January 2, 2018
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Chin-Kai Chuang, Yu-Hsyu Su, Tai-Yun Lin
  • Patent number: 9850470
    Abstract: Disclosed is a novel polyene-specific glycosyltransferase derived from Pseudonocardia autotrophica. The glycosyltransferase includes an amino acid sequence of SEQ ID NO: 1 and a gene encoding the glycosyltransferase. The glycosyltransferase is produced by a method which includes the steps of: culturing transgenic recombinant microorganisms; and isolating glycosyltransferase from the cultured recombinant microorganisms.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: December 26, 2017
    Assignee: INHA-INDUSTRY PARTNERSHIP INSTITUTE
    Inventors: Eung Soo Kim, Mi Jin Lee, Hye Jin Kim
  • Patent number: 9827287
    Abstract: The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: November 28, 2017
    Assignee: BIOMARCK PHARMACEUTICALS, LTD.
    Inventor: Indu Parikh
  • Patent number: 9764018
    Abstract: The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: September 19, 2017
    Assignee: GLYCOVAXYN AG
    Inventors: Michael Wacker, Charles Waechter
  • Patent number: 9719121
    Abstract: Reaction solutions are disclosed herein comprising water, incompletely refined sucrose, and a glucosyltransferase enzyme that synthesizes insoluble poly alpha-1,3-glucan having at least 50% alpha-1,3 glycosidic linkages and a weight average degree of polymerization (DPw) of at least 100. The yield of poly alpha-1,3-glucan by a reaction solution herein is at least 7% of the weight of sucrose that was converted in the reaction solution. Further disclosed are methods of producing poly alpha-1,3-glucan using incompletely refined sucrose, and poly alpha-1,3-glucan produced by these methods.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: August 1, 2017
    Assignee: EI DU PONT DE NEMOURS AND COMPANY
    Inventors: Dean M Fake, Susan Marie Hennessey, Brian D Mather, Jennifer S Ovental, Wayne Atkinson, Tyler D Pritchett, Negash Adugna
  • Patent number: 9688954
    Abstract: The present invention relates to the enzymatic synthesis of oligosaccharides, particularly, sialylated oligosaccharides comprising the carbohydrate moeities of the gangliosides GM3, GD3, and GT3.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: June 27, 2017
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventor: Eric Samain
  • Patent number: 9683016
    Abstract: PSF 1-derived peptides and pharmaceutical compositions of the peptides are described for immunotherapy of cancer patients. The peptides and pharmaceutical compositions containing these peptides induce a CTL response for treating or preventing cancer.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: June 20, 2017
    Assignees: GENESTEM CO., LTD., OSAKA URBAN INDUSTRY PROMOTION CENTER
    Inventors: Hidekazu Tanaka, Motofumi Iguchi, Mari Yokoyama
  • Patent number: 9670500
    Abstract: This disclosure provides transgenic plants having enhanced traits such as increased yield, increased nitrogen use efficiency and enhanced drought tolerance; propagules, progeny and field crops of such transgenic plants; and methods of making and using such transgenic plants. This disclosure also provides methods of producing hybrid seed from such transgenic plants, growing such seed and selecting progeny plants with enhanced traits. Also disclosed are transgenic plants with altered phenotypes which are useful for screening and selecting transgenic events for the desired enhanced trait.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: June 6, 2017
    Assignee: Monsanto Technology LLC
    Inventor: Mark Scott Abad
  • Patent number: 9657322
    Abstract: The invention relates to the field of poly-and oligosaccharides and their nutritional effects. In particular, it relates to the application of ?-glucanotransferases in methods for preparing dietary fibers, including prebiotic oligosaccharides, and to novel oligosaccharides obtainable thereby. Provided is a method for producing a mixture of gluco-oligosaccharides having one or more consecutive (?1?6) glucosidic linkages and one or more consecutive (?1?4) glucosidic linkages, comprising contacting a poly- and/or oligosaccharide substrate comprising at least two (?1?4) linked D-glucose units with an ?-glucanotransferase capable of cleaving (?1?4) glucosidic linkages and making new (?1?4) and (?1?6) glucosidic linkages. Also provided are (isolated) gluco-oligosaccharides obtainable thereby, and their application in nutritional and cosmetic compositions.
    Type: Grant
    Filed: May 10, 2010
    Date of Patent: May 23, 2017
    Assignee: RIJKSUNIVERSITEIT GRONINGEN
    Inventors: Lubbert Dijkhuizen, Marc Jos Elise Cornelis van der Maarel, Johannis Paulus Kamerling, Reinder Johannes Leemhuis, Slavko Kralj, Justyna Malgorzata Dobruchowska
  • Patent number: 9657045
    Abstract: A process for enabling the production of a particulate composition containing crystalline trehalose dihydrate is provided. Including allowing an ?-glycosyltrehalose-forming enzyme to act on liquefied starch derived from a microorganism of the genus Arthrobacter and a trehalose-releasing enzyme derived from a microorganism of the genus Arthrobacter along with a starch debranching enzyme and a cyclomaltodextrin glucanotransferase; allowing glucoamylase to act on the resulting mixture to obtain a saccharide solution containing ?,?-trehalose; precipitating crystalline ?,?-trehalose dihydrate from the above saccharide solution; collecting the precipitated crystalline ?,?-trehalose dihydrate by a centrifuge; and ageing and drying the collected crystals. Cyclomaltodextrin glucanotransferase derived from a microorganism of the genus Paenibacillus or a mutant enzyme thereof is used to increase the ?,?-trehalose content in the saccharide solution to over 86.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: May 23, 2017
    Assignee: HAYASHIBARA CO., LTD.
    Inventors: Takashi Shibuya, Seisuke Izawa